Active	Status	Sponsor type	Region	Phase	Filter
18 Active 11 Inactive 29 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cheng, Wei
ENREACH-PDAC-01, NCT05149326: KN046 in Subjects With Advanced Pancreatic Ductal Adenocarcinoma.	Active, not recruiting	3	408	RoW	KN046, placebo	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	Advanced Pancreatic Ductal Adenocarcinoma	04/24	08/24
NCT05911217: A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer	Recruiting	1	20	RoW	CT041 autologous CAR T-cell injection, Single Group Assignment	CARsgen Therapeutics Co., Ltd., Fudan University	Pancreatic Cancer	12/26	12/26
Long, Yun
NCT06351150: Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock	Not yet recruiting	3	214	RoW	Angiotensin II Injection, 0.9% sodium chloride injection	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Vasodilatory Shock	06/27	12/27